EFFICACY AND SAFETY OF GUSELKUMAB TN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY

被引：0

作者：

Coates, Laura C. ^{[1
]}

Gossec, Laure ^{[2
]}

Theander, Elke ^{[3
]}

Bergmans, Paul ^{[4
]}

Neuhold, Marlies ^{[5
]}

Karyekar, Chetan S. ^{[6
]}

Shawi, May ^{[6
]}

Noel, Wim ^{[5
]}

Schett, Georg ^{[7
]}

McInnes, Iain B. ^{[8
]}

机构：

[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England

[2] Sorbonne Univ, Dept Rheumatol, Paris, France

[3] Janssen Sci Affairs LLC, Dept Immunol, Solna, Sweden

[4] Janssen, Dept Biostat, Breda, Netherlands

[5] Janssen Sci Affairs LLC, Dept Immunol, Brussels, Belgium

[6] Janssen Global Serv LLC, Dept Immunol, Horsham, PA USA

[7] FAU Erlangen Nurnberg, Dept Internal Med 3, Nurnberg, Germany

[8] Univ Glasgow, Dept Immunol, Glasgow, Lanark, Scotland

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2021年 / 27卷

关键词：

DOUBLE-BLIND;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PANLAR2021

引用

页码：S106 / S107

页数：2

共 50 条

[21] SUSTAINED RESPONSE TO GUSELKUMAB REGARDLESS OF BASELINE DEMOGRAPHIC, DISEASE, AND MEDICATION CHARACTERISTICS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TNF INHIBITORS: RESULTS FROM A PHASE 3B TRIAL
Mcinnes, I.
Sewerin, P.
Sharaf, M.
Efficace, M.
Shawi, M.
Perate, M.
Zimmermann, M.
Coates, L.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1784 - 1785
[22] Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients With Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results From a Phase 3B Trial
McInnes, Iain
Sewerin, Philipp
Richard, Nicolas
Sharaf, Mohamed
Efficace, Michela
Shawi, May
Perate, Michelle
Zimmermann, Miriam
Coates, Laura
JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 80 - 80
[23] Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
McInnes, Iain B.
Sewerin, Philipp
Sharaf, Mohamed
Efficace, Michela
Shawi, May
Perate, Michelle
Zimmermann, Miriam
Coates, Laura
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4241 - 4244
[24] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: SUMMARY RESULTS FROM THE 24-WEEK PHASE III RA-BEACON STUDY
Zamani, Omid
Combe, Bernard
Tony, Hans-Peter
Sanchez Burson, Juan
Tahir, Hasan
Ostergaard, Mikkel
Augendre-Ferrante, Beatrice
Beselin, Anke
Larsson, Esbjorn
Casillas, Marta
Smolen, Josef
RHEUMATOLOGY, 2016, 55 : 93 - 93
[25] EFFICACY AND SAFETY OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDs: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 TRIAL
Kristensen, L. E.
Keiserman, M.
Papp, K.
Mccasland, L.
White, D.
Barcomb, L.
Lu, W.
Wang, Z.
Soliman, A. M.
Eldred, A.
Behrens, F.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1315 - 1316
[26] Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials
Huang, Yanrong
Fan, Yong
Liu, Yang
Xie, Wenhui
Zhang, Zhuoli
CLINICAL RHEUMATOLOGY, 2019, 38 (10) : 2765 - 2776
[27] Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Gladman, Dafna D.
Rigby, William
Azevedo, Valderilio F.
Behrens, Frank
Blanco, Ricardo
Kaszuba, Andrzej
Kudlacz, Elizabeth
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
Kanik, Keith S.
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[28] Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials
Yanrong Huang
Yong Fan
Yang Liu
Wenhui Xie
Zhuoli Zhang
Clinical Rheumatology, 2019, 38 : 2765 - 2776
[29] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: OPAL Beyond, a randomized, double blind, placebo-controlled, phase 3 trial
Gladman, Dafna
Rigby, William
Azevedo, Valderilio
Behrens, Frank
Blanco, Ricardo
Kaszuba, Andrzej
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB114 - AB114
[30] Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study
Ritchlin, Christopher T.
Deodhar, Atul
Boehncke, Wolf-Henning
Soriano, Enrique R.
Kollmeier, Alexa P.
Xu, Xie L.
Zazzetti, Federico
Shawi, May
Jiang, Yusang
Sheng, Shihong
Helliwell, Philip S.
ACR OPEN RHEUMATOLOGY, 2023, 5 (03) : 149 - 164

← 1 2 3 4 5 →